Jennifer M. Puck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennifer M. Puck has a total of 595 co-authors. Here are the top co-authors by number of shared publications:
- Luigi Daniele Notarangelo
Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States
12 shared publications - Morton J. Cowan
Division of Pediatric Allergy, Immunology, and Blood and Marrow Transplantation, https://ror.org/043mz5j54University of California, San Francisco, San Francisco, CA, USA
10 shared publications - Christopher C. Dvorak
Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation University of California San Francisco San Francisco California USA
7 shared publications - Morna J. Dorsey
Division of Pediatric Allergy, Immunology, and Blood and Marrow Transplantation, https://ror.org/043mz5j54University of California, San Francisco, San Francisco, CA, USA
7 shared publications - Christen L. Ebens
Division of Pediatric Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN, USA
6 shared publications - Donald Barry Kohn
University of California, Los Angeles, Los Angeles, California, UNITED STATES
6 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 17, 1984349
Host genomics in diagnosing inborn errors of immunity and tailoring infectious disease treatments
Genomic technologies are widely applied clinically to identify pathogens and their antimicrobial susceptibilities, but less use is made of patients’ germline genomic variations in infectious disease management. Not only can inborn errors of immunity (IEIs), most of which are rare, be detected before severe complications develop, but host genomics can assist with risk stratification for severe common infections, antimicrobial therapy selection, and pharmacogenomic-guided dosing. Over 30 clinical immunologists, infectious disease specialists and geneticists met to outline challenges and opportunities concerning host genomics and infectious diseases. Obstacles identified included payer requirements for extensive conventional diagnostics prior to genetic testing, lack of electronic health record (EHR) interoperability, and limited evidence of efficacy and cost-effectiveness given the individual rarity of most IEIs. Priorities to broaden the use of host genomics include publicizing indicators of IEIs, building them into EHR informatics systems, and promoting multidisciplinary approaches to identifying patients with IEIs.
- 28 October 2026
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 17, 1984349
Open AccessHost genomics in diagnosing inborn errors of immunity and tailoring infectious disease treatments
Genomic technologies are widely applied clinically to identify pathogens and their antimicrobial susceptibilities, but less use is made of patients’ germline genomic variations in infectious disease management. Not only can inborn errors of immunity (IEIs), most of which are rare, be detected before severe complications develop, but host genomics can assist with risk stratification for severe common infections, antimicrobial therapy selection, and pharmacogenomic-guided dosing. Over 30 clinical immunologists, infectious disease specialists and geneticists met to outline challenges and opportunities concerning host genomics and infectious diseases. Obstacles identified included payer requirements for extensive conventional diagnostics prior to genetic testing, lack of electronic health record (EHR) interoperability, and limited evidence of efficacy and cost-effectiveness given the individual rarity of most IEIs. Priorities to broaden the use of host genomics include publicizing indicators of IEIs, building them into EHR informatics systems, and promoting multidisciplinary approaches to identifying patients with IEIs.
- 26 October 2026
- Published by Elsevier in Genetics in Medicine
Selection of Genetic Conditions for Multi-State Genomic Newborn Screening in BRIDGES-NBS
- 26 October 2026
- Published by Elsevier in Genetics in Medicine
Selection of Genetic Conditions for Multi-State Genomic Newborn Screening in BRIDGES-NBS
- Open Access
Trajectory of Hyper IgE complications
Objective Our objective was to define the natural history of hyper IgE syndrome. Well, there have been a number of large cross-sectional studies. It has been difficult to provide anticipatory care for the growing adult population. Methods The USIDNET registry was used to identify patients with hyper IgE syndrome. We evaluated all patients regardless of genetic etiology. Complications were extracted as text from the problem list or ICD codes, and each complication was date stamped, which allowed us to estimate the age at which the complication arose. Results Many of the complications previously identified were seen in this cohort. The most feared complications were uncommon, however, developmental delay and psychosis affected nearly a fifth of the cohort which has not been previously reported. Conclusions As the number of adults with hyper IgE syndrome increases our awareness of late onset complications is important. Aspergillus and pneumatoceles were less common than seen in some other cohorts. However, the significant rate of psychosis will represent a significant challenge for clinicians.
Open AccessTrajectory of Hyper IgE complications
Objective Our objective was to define the natural history of hyper IgE syndrome. Well, there have been a number of large cross-sectional studies. It has been difficult to provide anticipatory care for the growing adult population. Methods The USIDNET registry was used to identify patients with hyper IgE syndrome. We evaluated all patients regardless of genetic etiology. Complications were extracted as text from the problem list or ICD codes, and each complication was date stamped, which allowed us to estimate the age at which the complication arose. Results Many of the complications previously identified were seen in this cohort. The most feared complications were uncommon, however, developmental delay and psychosis affected nearly a fifth of the cohort which has not been previously reported. Conclusions As the number of adults with hyper IgE syndrome increases our awareness of late onset complications is important. Aspergillus and pneumatoceles were less common than seen in some other cohorts. However, the significant rate of psychosis will represent a significant challenge for clinicians.
- Open Access
- 7 July 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (5) , e20250231
Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Winestone et al. demonstrate that in 796 children with SCID transplanted with nonsibling donors between 1982 and 2020, survival was 18.8% lower among Black patients, 14.4% lower among Asian/Pacific Islander patients, and 6.9% lower among Hispanic patients compared with non-Hispanic White patients (P < 0.01). Newborn screening for SCID mitigates wide disparities between Black and non-Hispanic White patients.
- 7 July 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (5) , e20250231
Open AccessNewborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Winestone et al. demonstrate that in 796 children with SCID transplanted with nonsibling donors between 1982 and 2020, survival was 18.8% lower among Black patients, 14.4% lower among Asian/Pacific Islander patients, and 6.9% lower among Hispanic patients compared with non-Hispanic White patients (P < 0.01). Newborn screening for SCID mitigates wide disparities between Black and non-Hispanic White patients.
- Open Access
CRISPR-mediated functional mapping of IL2RG variants in primary human T cells predicts X-linked severe combined immunodeficiency
Distinguishing pathogenic from benign mutation is critical for genetic diagnosis. A CRISPR-targeted saturation genome editing (SGE) platform in primary human cells assessed 489 single nucleotide variants (SNVs) in exon 5 of IL2RG, the gene causing X-linked SCID. The functional impact was clearly defined for 470 variants, agreeing with 100% (18/18) of ClinVar-deposited benign or likely benign annotations, and 100% (42/42) of pathogenic or likely pathogenic annotations. We discovered 90 novel loss-of-function mutations and validated an expected block in T-lymphocyte differentiation from edited hematopoietic stem cells.
Open AccessCRISPR-mediated functional mapping of IL2RG variants in primary human T cells predicts X-linked severe combined immunodeficiency
Distinguishing pathogenic from benign mutation is critical for genetic diagnosis. A CRISPR-targeted saturation genome editing (SGE) platform in primary human cells assessed 489 single nucleotide variants (SNVs) in exon 5 of IL2RG, the gene causing X-linked SCID. The functional impact was clearly defined for 470 variants, agreeing with 100% (18/18) of ClinVar-deposited benign or likely benign annotations, and 100% (42/42) of pathogenic or likely pathogenic annotations. We discovered 90 novel loss-of-function mutations and validated an expected block in T-lymphocyte differentiation from edited hematopoietic stem cells.
- Open Access
- 2 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (5) , 1783-1798
Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report
Wiskott-Aldrich syndrome (WAS), an X-linked disorder characterized by immunodeficiency, thrombocytopenia, autoimmunity, and malignancy, can be effectively treated with allogeneic hematopoietic cell transplantation (HCT). Older age at HCT and mismatched donors are known to affect overall survival (OS). However, the influence of specific clinical manifestations or WAS variant class on OS and factors associated with event-free survival (EFS) remain incompletely defined. We analyzed outcomes of 308 patients with WAS who underwent HCT at 37 institutions of the Primary Immune Deficiency Treatment Consortium from 1990 to 2018. With a median follow-up of 5.3 years, the 5-year OS and EFS were 87.2% and 79.7%, respectively. Age ≥5 years, donor type, and a pre-HCT history of severe infection had a negative impact on OS and EFS, whereas pre-HCT autoimmunity had no impact. Reduced-intensity regimens were associated with lower T-cell and myeloid donor chimerism, particularly when non–busulfan-based regimens were used. Low myeloid donor chimerism was associated with lower platelet counts. Mixed chimerism was not consistently associated with post-HCT autoimmunity. Patients with class I (exon 1-2 missense and intron 5 hot spot variants) and class II variants (all others) had similar pre-HCT clinical symptom severity and no difference in OS, EFS, or platelet recovery post-HCT. In conclusion, our study showed excellent long-term OS and EFS after HCT for WAS, highlighting the importance of early HCT, before the development of severe infections. We confirmed that HCT using busulfan-based conditioning was associated with improved donor chimerism and platelet recovery. This trial was registered at www.clinicaltrials.gov as NCT02064933.
- 2 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (5) , 1783-1798
Open AccessHematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report
Wiskott-Aldrich syndrome (WAS), an X-linked disorder characterized by immunodeficiency, thrombocytopenia, autoimmunity, and malignancy, can be effectively treated with allogeneic hematopoietic cell transplantation (HCT). Older age at HCT and mismatched donors are known to affect overall survival (OS). However, the influence of specific clinical manifestations or WAS variant class on OS and factors associated with event-free survival (EFS) remain incompletely defined. We analyzed outcomes of 308 patients with WAS who underwent HCT at 37 institutions of the Primary Immune Deficiency Treatment Consortium from 1990 to 2018. With a median follow-up of 5.3 years, the 5-year OS and EFS were 87.2% and 79.7%, respectively. Age ≥5 years, donor type, and a pre-HCT history of severe infection had a negative impact on OS and EFS, whereas pre-HCT autoimmunity had no impact. Reduced-intensity regimens were associated with lower T-cell and myeloid donor chimerism, particularly when non–busulfan-based regimens were used. Low myeloid donor chimerism was associated with lower platelet counts. Mixed chimerism was not consistently associated with post-HCT autoimmunity. Patients with class I (exon 1-2 missense and intron 5 hot spot variants) and class II variants (all others) had similar pre-HCT clinical symptom severity and no difference in OS, EFS, or platelet recovery post-HCT. In conclusion, our study showed excellent long-term OS and EFS after HCT for WAS, highlighting the importance of early HCT, before the development of severe infections. We confirmed that HCT using busulfan-based conditioning was associated with improved donor chimerism and platelet recovery. This trial was registered at www.clinicaltrials.gov as NCT02064933.
- Open Access
- 2 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 887-900
Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC
The Primary Immune Deficiency Treatment Consortium performed a retrospective analysis of 133 patients with severe combined immunodeficiency (SCID) receiving matched sibling donor (MSD) hematopoietic cell transplantation (HCT) between 1980 and 2023 at 30 North American institutions. In this largest cohort of MSD outcomes in patients with SCID to date, we examined the impact of conditioning regimen and graft-versus-host disease (GVHD) prophylaxis on survival and immune recovery. Outcomes after MSD HCT for SCID were excellent. Patients without an active infection or failure to thrive (FTT) at the time of HCT had 5-year overall survival superior to those with infection or FTT. Acute and chronic GVHD outcomes were independent of GVHD prophylaxis, conditioning regimen, SCID type, or presence of maternal engraftment. Patients without active infection at the time of HCT had superior chronic GVHD-free event-free survival vs those with infection. T-cell reconstitution at 6 months was less likely achieved with use of GVHD prophylaxis or serotherapy, and in patients with leaky SCID or Omenn syndrome. At 6 months, 1 year, and 2-5 years, T-cell reconstitution was less likely with ADA, DCLRE1C, or RAG genotype. B-cell reconstitution at 1 year and 2-5 years was negatively affected by development of grade 2 to 4 or 3 to 4 acute GVHD. Conditioning did not affect T- or B-cell reconstitution. Our data suggest omitting conditioning and GVHD prophylaxis for patients with typical SCID did not negatively affect 5-year outcomes after MSD HCT, but the data are insufficient to recommend this approach for best long-term outcomes. This trial was registered at www.clinicaltrials.gov as #NCT01186913 and #NCT01346150.
- 2 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 887-900
Open AccessOutcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC
The Primary Immune Deficiency Treatment Consortium performed a retrospective analysis of 133 patients with severe combined immunodeficiency (SCID) receiving matched sibling donor (MSD) hematopoietic cell transplantation (HCT) between 1980 and 2023 at 30 North American institutions. In this largest cohort of MSD outcomes in patients with SCID to date, we examined the impact of conditioning regimen and graft-versus-host disease (GVHD) prophylaxis on survival and immune recovery. Outcomes after MSD HCT for SCID were excellent. Patients without an active infection or failure to thrive (FTT) at the time of HCT had 5-year overall survival superior to those with infection or FTT. Acute and chronic GVHD outcomes were independent of GVHD prophylaxis, conditioning regimen, SCID type, or presence of maternal engraftment. Patients without active infection at the time of HCT had superior chronic GVHD-free event-free survival vs those with infection. T-cell reconstitution at 6 months was less likely achieved with use of GVHD prophylaxis or serotherapy, and in patients with leaky SCID or Omenn syndrome. At 6 months, 1 year, and 2-5 years, T-cell reconstitution was less likely with ADA, DCLRE1C, or RAG genotype. B-cell reconstitution at 1 year and 2-5 years was negatively affected by development of grade 2 to 4 or 3 to 4 acute GVHD. Conditioning did not affect T- or B-cell reconstitution. Our data suggest omitting conditioning and GVHD prophylaxis for patients with typical SCID did not negatively affect 5-year outcomes after MSD HCT, but the data are insufficient to recommend this approach for best long-term outcomes. This trial was registered at www.clinicaltrials.gov as #NCT01186913 and #NCT01346150.
- Open Access
- 17 December 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (1)
Neurodevelopmental outcomes following hematopoietic cell transplantation for patients with severe combined immunodeficiency (SCID): A PIDTC study
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for severe combined immunodeficiency (SCID). Since the initiation of newborn screening (NBS), survival rates have improved significantly, but the impact of HCT upon neurodevelopment for patients with SCID requires more investigation. We performed a cross-sectional study of subjects with SCID in North America to assess the impact of NBS, transplant conditioning regimen, and genotype on neurodevelopmental outcomes after HCT. 69 subjects with SCID from 17 PIDTC centers (excluding those with ADA deficiency), ages 6–16 years, received comprehensive standardized neurodevelopmental testing of cognitive, behavioral, and emotional function. Compared with the normative population, our subjects performed in the average range. We found no impact of NBS, chemotherapy conditioning, or genotype. Multivariate analysis revealed a significant decrease in IQ in subjects whose families earned <$50,000 per year. We recommend that children treated by HCT for SCID be monitored with periodic cognitive and behavioral assessments for deficits that could potentially impact long-term ND outcomes.
- 17 December 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (1)
Open AccessNeurodevelopmental outcomes following hematopoietic cell transplantation for patients with severe combined immunodeficiency (SCID): A PIDTC study
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for severe combined immunodeficiency (SCID). Since the initiation of newborn screening (NBS), survival rates have improved significantly, but the impact of HCT upon neurodevelopment for patients with SCID requires more investigation. We performed a cross-sectional study of subjects with SCID in North America to assess the impact of NBS, transplant conditioning regimen, and genotype on neurodevelopmental outcomes after HCT. 69 subjects with SCID from 17 PIDTC centers (excluding those with ADA deficiency), ages 6–16 years, received comprehensive standardized neurodevelopmental testing of cognitive, behavioral, and emotional function. Compared with the normative population, our subjects performed in the average range. We found no impact of NBS, chemotherapy conditioning, or genotype. Multivariate analysis revealed a significant decrease in IQ in subjects whose families earned <$50,000 per year. We recommend that children treated by HCT for SCID be monitored with periodic cognitive and behavioral assessments for deficits that could potentially impact long-term ND outcomes.
- Open Access
- 19 November 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (1)
Automated data extraction model for the USIDNET registry: Bigger, faster, and better data collection
The United States Immunodeficiency Network (USIDNET) is an NIH-funded research consortium that advances scientific investigation on inborn errors of immunity (IEIs). Formerly, USIDNET registry data were collected via an opt-in system with patient informed consent. The current registry uses semiautomated, de-identified data extraction from EPIC with a consent waiver. This study was performed to assess whether the new method improved enrollment using data from one site. Diagnoses, sex, and age within the new (n = 2,796) and old (n = 551) registries were defined. The new registry enrolled more subjects and had six times more clinical features recorded per patient on average and 22 times more laboratory data recorded per patient. Response to queries is much more rapid, with execution of a database query within a day. There were differences in enrollment demographics depending on underlying diagnosis. The design of the new USIDNET registry may better capture a greater number and representation of patients compared to the old registry.
- 19 November 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (1)
Open AccessAutomated data extraction model for the USIDNET registry: Bigger, faster, and better data collection
The United States Immunodeficiency Network (USIDNET) is an NIH-funded research consortium that advances scientific investigation on inborn errors of immunity (IEIs). Formerly, USIDNET registry data were collected via an opt-in system with patient informed consent. The current registry uses semiautomated, de-identified data extraction from EPIC with a consent waiver. This study was performed to assess whether the new method improved enrollment using data from one site. Diagnoses, sex, and age within the new (n = 2,796) and old (n = 551) registries were defined. The new registry enrolled more subjects and had six times more clinical features recorded per patient on average and 22 times more laboratory data recorded per patient. Response to queries is much more rapid, with execution of a database query within a day. There were differences in enrollment demographics depending on underlying diagnosis. The design of the new USIDNET registry may better capture a greater number and representation of patients compared to the old registry.
- Open Access
- 15 October 2025
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (1) , 101613
The ClinGen Severe Combined Immunodeficiency Disease Variant Curation Expert Panel: Specifications for classification of variants in ADA, DCLRE1C, IL2RG, IL7R, JAK3, RAG1, and RAG2
- 15 October 2025
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (1) , 101613
Open AccessThe ClinGen Severe Combined Immunodeficiency Disease Variant Curation Expert Panel: Specifications for classification of variants in ADA, DCLRE1C, IL2RG, IL7R, JAK3, RAG1, and RAG2